Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lupkynis
Pharma
Aurinia deal with Teva keeps Lupkynis generic in check until '36
Aurinia has struck a patent settlement with Teva that will likely ensure that Lupkynis will not face generic competition in the U.S. until late 2036.
Kevin Dunleavy
Aug 20, 2026 11:28am
George Tidmarsh exits as LinkedIn post sparks lawsuit, probe
Nov 3, 2025 11:13am
FDA official chastises Aurinia med in now-deleted LinkedIn post
Sep 30, 2025 10:15am
Autoimmune drugmaker Aurinia lays off 45% of workforce
Nov 7, 2024 9:44am
Aurinia quells investor unrest, names former CEO Foster to board
Sep 21, 2023 10:55am
Aurinia launches 'uncomfortable' kidney health campaign
Oct 25, 2022 9:15am
